Dabrafenib in BRAFV600E mutant pilocytic astrocytoma
Sign Up to like & getrecommendations! Published in 2020 at "Child's Nervous System"
DOI: 10.1007/s00381-020-04527-4
Abstract: Dear Editor: We read the report on “Dabrafenib in BRAFV600E mutant pilocytic astrocytoma (PA) in a pediatric patient” with a great interest [1]. Mustansir et al. concluded that “We report a case of successful treatment… read more here.
Keywords: pilocytic astrocytoma; dabrafenib; mutant pilocytic; dabrafenib brafv600e ... See more keywords
Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
Sign Up to like & getrecommendations! Published in 2020 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2020.100668
Abstract: INTRODUCTION Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low… read more here.
Keywords: anaplastic thyroid; dabrafenib; case; rechallenge ... See more keywords
Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2020.113718
Abstract: A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of dabrafenib (DAB), its main metabolite hydroxy-dabrafenib (OHD) and trametinib (TRA) in human plasma has been developed and validated. After addition of internal… read more here.
Keywords: chromatography tandem; plasma; dabrafenib; mass spectrometry ... See more keywords
Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
Sign Up to like & getrecommendations! Published in 2021 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2021.115797
Abstract: Dabrafenib is a BRAF inhibitor used in combination treatment of malignant melanoma and non-small cell lung carcinoma. In this study, we aimed to characterize its interactions with cytochrome P450 (CYP) isoenzymes and ATP-binding cassette (ABC)… read more here.
Keywords: combination; inhibits abcg2; dabrafenib inhibits; dabrafenib ... See more keywords
Dabrafenib- and trametinib-associated glomerular toxicity
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000028485
Abstract: Abstract Rationale: Combined treatment with dabrafenib, a B-RAF inhibitor, and trametinib, a mitogen-activated protein kinase inhibitor, is an effective option for patients with metastatic melanoma. A few cases of acute kidney injury associated with tubulointerstitial… read more here.
Keywords: dabrafenib; kidney; dabrafenib trametinib; metastatic melanoma ... See more keywords
Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137531
Abstract: BACKGROUND: Hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder. The BRAF V600E mutation was shown to be the underlying genetic driver for the vast majority of classical HCL (HCLc) cases and treatment… read more here.
Keywords: response; dabrafenib; treatment; therapy ... See more keywords
Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.01000
Abstract: PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as… read more here.
Keywords: safety; braf v600; combination; trametinib ... See more keywords
Dabrafenib Induced Pancreatitis: A Rare Event During RAI- Refractory Treatment of Metastatic Papillary Thyroid Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvab048.1814
Abstract: Dabrafenib, a BRAF selective tyrosine kinase inhibitor (TKI) has been associated with pancreatitis alone, and in combination with trametinib (a MEK pathway inhibitor). We report a case of dabrafenib induced acute pancreatitis in a patient… read more here.
Keywords: pancreatitis; treatment; dabrafenib; thyroid cancer ... See more keywords
Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Medicina"
DOI: 10.3390/medicina58040511
Abstract: Dabrafenib and trametinib are two available molecules that have been approved for the treatment of metastatic melanoma with BRAF-V600E or V600K mutations. Their combined therapy has led to long-lasting survival benefits and substantially improved outcomes.… read more here.
Keywords: desensitization; dabrafenib; desensitization protocols; metastatic melanoma ... See more keywords
Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury
Sign Up to like & getrecommendations! Published in 2018 at "Neural Regeneration Research"
DOI: 10.4103/1673-5374.226394
Abstract: Ischemic brain injury triggers neuronal cell death by apoptosis via caspase activation and by necroptosis through activation of the receptor-interacting protein kinases (RIPK) associated with the tumor necrosis factor-alpha (TNF-α)/death receptor. Recent evidence shows RIPK… read more here.
Keywords: inhibitor; dabrafenib; ischemic brain; brain injury ... See more keywords